Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform

Core Insights - Trinity Biotech has made significant advancements in its next-generation Continuous Glucose Monitoring (CGM) system, CGM+, which is moving towards regulatory submissions and commercialization [1][9] - The company anticipates initiating a pivotal clinical trial in 2026, following positive results from previous trials [1][12] Technical Advancements - The updated electronics architecture has led to a substantial improvement in glucose measurement accuracy, achieving a material reduction in Mean Absolute Relative Difference (MARD) during multi-day wear [4][7] - The incorporation of advanced electronic components supports a unique multimodal data-capture capability, enabling AI-driven analytics for personalized metabolic health insights [5][11] Market Positioning - CGM+ is positioned to participate in the rapidly growing $15 billion CGM market, with projections indicating growth from $15.3 billion in 2026 to $31.4 billion by 2031, reflecting a CAGR of 15.4% [7][15] - The device's modular design aims to reduce costs and improve sustainability compared to current market-leading CGMs, addressing one of the main barriers to broader adoption [6][9] Innovation and Collaboration - The company is collaborating with clinicians, scientists, and digital health leaders to optimize the CGM+ architecture, which is designed to collect multiple physiological metrics alongside glucose [11] - Feedback from stakeholders has been enthusiastic, prompting the company to advance the CGM+ program through its final design phase [12]